CA2247453A1 - Azolobenzazepine derivatives as neurologically active agents - Google Patents

Azolobenzazepine derivatives as neurologically active agents Download PDF

Info

Publication number
CA2247453A1
CA2247453A1 CA002247453A CA2247453A CA2247453A1 CA 2247453 A1 CA2247453 A1 CA 2247453A1 CA 002247453 A CA002247453 A CA 002247453A CA 2247453 A CA2247453 A CA 2247453A CA 2247453 A1 CA2247453 A1 CA 2247453A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
chloro
dione
benzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002247453A
Other languages
English (en)
French (fr)
Inventor
Joseph James Lewis
William Jackson Frazee
Marc Jerome Chapdelaine
Laura Enid Garcia-Davenport
Kelly Anne Brush
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2247453A1 publication Critical patent/CA2247453A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002247453A 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents Abandoned CA2247453A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1352896P 1996-03-08 1996-03-08
US60/013528 1996-03-08

Publications (1)

Publication Number Publication Date
CA2247453A1 true CA2247453A1 (en) 1997-09-12

Family

ID=21760422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247453A Abandoned CA2247453A1 (en) 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents

Country Status (13)

Country Link
US (2) US6124281A (enExample)
EP (1) EP0888350A1 (enExample)
JP (1) JP2000506160A (enExample)
KR (1) KR19990087585A (enExample)
CN (1) CN1084747C (enExample)
AU (1) AU723860B2 (enExample)
CA (1) CA2247453A1 (enExample)
IL (1) IL126095A0 (enExample)
NO (1) NO984106L (enExample)
NZ (1) NZ330973A (enExample)
TW (1) TW486480B (enExample)
WO (1) WO1997032883A1 (enExample)
ZA (1) ZA971964B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004020A3 (en) * 1997-09-29 2002-12-28 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and their use as antiallergic agent
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
ES2312650T3 (es) 2001-12-26 2009-03-01 Meiji Seika Kaisha Ltd. Nuevo derivado de triazolobenzazepina triciclica cristalina.
AU2003212979A1 (en) * 2002-02-07 2003-09-02 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
RS52436B (sr) 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2468391T3 (es) 2008-12-22 2014-06-16 Millennium Pharmaceuticals, Inc. Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EP2536279A4 (en) 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
WO1995018130A1 (en) * 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
WO1997000258A1 (en) * 1995-06-15 1997-01-03 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine compounds

Also Published As

Publication number Publication date
CN1224424A (zh) 1999-07-28
WO1997032883A1 (en) 1997-09-12
TW486480B (en) 2002-05-11
IL126095A0 (en) 1999-05-09
AU723860B2 (en) 2000-09-07
NO984106D0 (no) 1998-09-07
EP0888350A1 (en) 1999-01-07
NO984106L (no) 1998-11-06
US6124281A (en) 2000-09-26
CN1084747C (zh) 2002-05-15
KR19990087585A (ko) 1999-12-27
AU2225397A (en) 1997-09-22
US6313290B1 (en) 2001-11-06
JP2000506160A (ja) 2000-05-23
NZ330973A (en) 2000-03-27
ZA971964B (en) 1997-09-08

Similar Documents

Publication Publication Date Title
CA2247453A1 (en) Azolobenzazepine derivatives as neurologically active agents
AU2017371200B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP1934214B1 (en) Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
CN105164114B (zh) C‑连接的杂环烷基取代的嘧啶类和它们的用途
JP4216905B2 (ja) Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
EP3461821B1 (en) Indole carboxamide compounds useful as kinase inhibitors
KR101864908B1 (ko) 피리다지논, 그의 제조 방법 및 사용 방법
CN1882591B (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
RU2378277C2 (ru) Производные пиразолпиримидина
TW200528455A (en) Azabicyclic heterocycles as cannabinoid receptor modulators
AU2018364938A1 (en) Macrocyclic compounds as TRK kinase inhibitors and uses thereof
JP2007217419A (ja) 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
CN101115755A (zh) 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
CN102131800A (zh) 5元和6元杂环化合物
EP0225013A1 (en) Heterocyclic compounds and their preparation and use
EA002755B1 (ru) Производные триазолопиридазина в качестве лигандов для гамк рецепторов
US6313125B1 (en) Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
CA2388658A1 (en) 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv
KR20190039781A (ko) 스피로환 함유 화합물 및 이의 약제학적 용도
WO2024067691A1 (zh) 含氮杂环类化合物及其医药用途
CA3023383A1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and use thereof
HUP0102894A2 (hu) Helyettesített triazolopiridazin-származék, valamint ilyen vegyületet tartalmazó gyógyászati készítmények
WO2024067694A1 (zh) 含氮杂环类化合物及其医药用途
DE69907923T2 (de) Triazolopyridazinderivate zur verbesserung der kognitiven funktionen
US6949549B2 (en) Imidazolophthalazine derivatives as ligands for GABAA receptors

Legal Events

Date Code Title Description
FZDE Discontinued